Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | Malignant cells | -0.497942 | 5.16e-32 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | pre | CD4+ T cells | 0.418317 | 8.51e-04 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | post | Malignant cells | 0.677014 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | Malignant cells | 0.914126 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
CLECL1 | taipale_tf_pairs__ETV5_CEBPD_NSCGGANNTTRCGYAAN_CAP | CEBPD; ETV5 (directAnnotation). |
CLECL1 | taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr | JUND (directAnnotation). |
CLECL1 | metacluster_167.7 | IRF8 (inferredBy_Orthology). |
CLECL1 | taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP | ETV5; FOXI1 (directAnnotation). |
CLECL1 | taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP | ELK1; TEF (directAnnotation). |
CLECL1 | transfac_pro__M05930 | ZNF286A (directAnnotation). |
CLECL1 | transfac_pro__M04722 | SPI1 (directAnnotation). |
CLECL1 | metacluster_16.7 | SOX10; SOX11; SOX14; SOX14; SOX15; SOX18; SOX2; SOX2; SOX21; SOX21; SOX21; SOX7; SOX7; SOX7; SOX8; SOX8; SOX9; SRY (directAnnotation). SOX1; SOX1; SOX10; SOX21; SOX3 (inferredBy_Orthology). |
CLECL1 | taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr | CEBPD; ETV2 (directAnnotation). |
CLECL1 | transfac_pro__M04746 | E2F1 (directAnnotation). |
CLECL1 | taipale_cyt_meth__KLF3_NRCCGCAGCCCN_FL_meth_repr | KLF3 (directAnnotation). |
CLECL1 | taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP | ETV5; HOXA2 (directAnnotation). |
CLECL1 | taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP | ETV5; EVX1 (directAnnotation). |
CLECL1 | jaspar__MA1708.1 | ETV7 (directAnnotation). |
CLECL1 | taipale_tf_pairs__HOXB2_ETV1_ACCGGAAATGA_CAP | ETV1; HOXB2 (directAnnotation). |
CLECL1 | tfdimers__MD00208 | IRF1; LTF (directAnnotation). |
CLECL1 | taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP | ELK3; FOXO1 (directAnnotation). |
CLECL1 | taipale__YY2_DBD_NNCCGCCATNW_repr | YY2 (directAnnotation). |
CLECL1 | metacluster_2.7 | IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology). |
CLECL1 | taipale_tf_pairs__ELK1_HOXA3_RSCGGTAATKR_CAP_repr | ELK1; HOXA3 (directAnnotation). |
CLECL1 | metacluster_160.18 | IRF6 (directAnnotation). |
CLECL1 | metacluster_119.1 | ZNF677 (directAnnotation). |
CLECL1 | dbtfbs__HLF_HepG2_ENCSR528PSI_merged_N1 | HLF (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |